Found 38 Leukemia trials
A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Featured study
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for …
Featured study
This study investigates a specific health condition to understand more about it and how it affects individuals. The purpose is to gather information that may be helpful for future research and treatments.The study focuses on evaluating the condition and collecting data to gain insights into its characteristics and impact on …
This study compares 2 combinations of drugs to prevent graft-versus-host disease (GVHD): Tacrolimus/methotrexate and Tacrolimus/mycophenolate mofetil/cyclophosphamide. Doctors want to know which combination is better or if they give the same results. The study will help doctors decide which treatment is best for future transplant patients. The purpose of its companion …
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.
This study is evaluating the safety and efficacy of UCART targeting CD123 in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of UCART123v1.2 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
This research study is being conducted to evaluate an experimental drug called PACE CART19 in patients with leukemia or lymphoma. PACE CART19 consists of cells from a healthy donor that are genetically modified and designed to target your cancer.
Request for collaborative review: WIRB serving as IRB of record.
Pleae refer to Section 3 (Objectives and Endpoints) of the full protocol Please refer to Section 3.1 (Primary Endpoint) of the full protocol Please refer to Section 3.2 (Secondary Endpoints) of the full protocol
This study tests the safety and effectiveness of the combination of ublituximab, umbralisib, and venetoclax. Patients with Chronic Lymphocytic Leukemia (CLL) will be invited to participate in this trial.
The study compares two acute graft-versus-host disease (aGVHD) prophylaxis regimens: CD24Fc/tacrolimus / methotrexate (CD24Fc/Tac/MTX) versus placebo/tacrolimus / methotrexate (placebo/Tac/MTX) in the setting of myeloablative conditioning (MAC), matched unrelated donor (MUD) allogeneic hematopoietic stem cell transplantation in participants with acute leukemia (AML/ALL) or myelodysplastic syndrome (MDS).
Please choose between Voice or SMS based delivery of verification code
or